TREM2 agonists are a novel class of immunomodulatory therapeutics targeting the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) pathway in Alzheimer's disease and other neurodegenerative conditions. TREM2 is primarily expressed on microglia in the brain and plays a critical role in modulating the brain's immune response to amyloid-beta pathology. Loss-of-function variants in the TREM2 gene (such as R47H, R62H) significantly increase Alzheimer's disease risk, making TREM2 activation a promising therapeutic strategy. [1]
TREM2 is a cell surface receptor on microglia that recognizes multiple ligands including amyloid-beta plaques, lipid particles, and apolipoprotein E (apoE). Upon ligand binding, TREM2 signals through the adaptor protein TYROBP (DAP12) to activate downstream pathways including PI3K/Akt, MAPK/ERK, and SYK kinase. This signaling drives critical microglial functions: [2]
The TREM2 agonist approach aims to bypass the need for functional TREM2 variants by delivering exogenous activation signals that restore or enhance microglial function. [3]
AL002 is a monoclonal antibody designed to activate TREM2 by binding to a distinct epitope that promotes receptor clustering and signaling. It represents the first TREM2-targeting antibody to enter clinical trials for Alzheimer's disease. [4]
AL003 uses a different mechanism, potentially acting as a TREM2-activating antibody with enhanced brain penetration. [5]
Several other companies have TREM2-targeting programs in various stages of development: [6]
| Agent | Company | Mechanism | Stage | [7]
|-------|---------|-----------|-------| [8]
| AL002 | Alector/AbbVie | TREM2 agonist mAb | Phase 2 | [9]
| AL003 | Alector | TREM2 agonist mAb | Phase 1 | [10]
| H3B-10252 | H3 Biomedicine | TREM2 mAb | Preclinical |
Soluble TREM2 (sTREM2) in cerebrospinal fluid reflects TREM2 shedding and microglial activation. CSF sTREM2 levels are elevated in early AD and correlate with disease progression.
Patients with TREM2 risk variants (R47H, R62H) may particularly benefit from TREM2 agonism:
TREM2 agonists are being tested in amyloid-positive patients, as amyloid plaques are the primary ligand for microglial phagocytosis.
Similar to other antibody therapies targeting immune pathways:
TREM2 agonists are being considered in combination with amyloid-targeting immunotherapies:
TREM2 agonists compete with other microglial-targeting approaches:
TREM2 agonism may have utility beyond Alzheimer's disease:
The study of Trem2 Agonists In Alzheimer Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.